FTC second request delays Sanara MedTech merger: 3 analysts hold Sanara MedTech stock

Published on 10/21/2026 at 03:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 28.14 million, up 8.93 percent year over year. Sanara MedTech stock has a USD 35.00 target.

Regulatory review and operating scale

The Federal Trade Commission requested more merger information on October 15, 2026.
Second-quarter revenue reached USD 28.14 million, up 8.93 percent year over year.
Sanara MedTech had a USD 304.5 million market capitalization as of October 20, 2026.
Three analysts rated the stock Hold with an average USD 35.00 target.

SMTI, US79957L1008, Illustration mit AI erstellt.

Sanara MedTech (US79957L1008) faces a longer regulatory path for its planned MiMedx merger after the Federal Trade Commission issued a Second Request on October 15, 2026. Markets Insider reported that the request extends the Hart-Scott-Rodino waiting period until 30 days after substantial compliance, unless the period ends earlier or is extended.

FTC review changes the timeline

The request adds a regulatory condition to a transaction that would leave Sanara MedTech as a wholly owned subsidiary of MiMedx. The companies said they continued to work constructively with the FTC, while completion remained subject to the waiting period and other closing conditions, according to TipRanks.

Three merger milestones carry figures

Sanara and MiMedx refiled their Hart-Scott-Rodino notification on September 15, 2026, restarting a 30-day waiting period. Shareholders then approved the merger on September 30, 2026, with 6,372,989 votes for the proposal out of 6,411,427 votes cast, as reported by StockWatch. The October 15, 2026 Second Request is the latest dated milestone.

What does the operating picture show?

Sanara MedTech reported USD 28.14 million of revenue for the second quarter of 2026, up 8.93 percent from the same quarter a year earlier. Net income was a USD 0.45 million loss, compared with net income of USD 0.46 million in the previous quarter, according to Investing.com.

That combination gives the merger review greater importance than the revenue comparison alone. The latest reported quarter produced USD 28.14 million of sales, but the company also posted negative net income and a USD 35.00 average analyst target.

Market value sets the scale

Sanara MedTech had a market capitalization of USD 304.5 million as of October 20, 2026. Its 52-week range was USD 16.05 to USD 35.52 on that date, placing the market value near the upper end of the observed range while the FTC process remains unresolved.